Previous Close | 13.22 |
Open | 13.11 |
Bid | 12.94 x 0 |
Ask | 13.15 x 0 |
Day's Range | 13.11 - 13.11 |
52 Week Range | 3.16 - 16.82 |
Volume | |
Avg. Volume | 98 |
Market Cap | N/A |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | May 07, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for 2LB.MU
Find out why investment banks up and down Wall Street have big expectations for these stocks.
A proposed bill in Congress targets Chinese biotech businesses that play an important role in developing drugs.
SAN CARLOS, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on March 22, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 97,700 shares of Iovance’s common stock to twenty new, non-ex